Luke Raphael Hoffman, MD, PhD

Luke Raphael Hoffman, MD, PhD

Pulmonary, Cystic Fibrosis Research, Cystic Fibrosis Program

On staff since September 2004

Children's Title: Director, Seattle Children's TDN Center for CF Microbiology

Academic Title: Associate Professor, Pediatrics

Research Center: Center for Clinical and Translational Research, Center for Respiratory Biology and Therapeutics

Language (Other than English): Spanish

  • Lucas R. Hoffman, MD, PhD, is attending physician at Seattle Children's Hospital and associate professor in the Department of Pediatrics at the University of Washington School of Medicine. Hoffman's research focuses on chronic lung infections, particularly in patients with cystic fibrosis (CF). Chronic infections have proven to be particularly difficult to treat with standard antibiotic therapies. For example, the lung infections in children with CF are not improved by antibiotics to the degree we would expect.

    Hoffman is working to understand why chronic lung infections are so difficult to treat and how to improve current treatments. Hoffman is also dedicated to the care of patients and to teaching medical students, residents and fellows. His areas of clinical expertise include asthma, CF, bronchopulmonary dysplasia, restrictive lung diseases and the pulmonary complications of neuromuscular disease. He is a member of the American Academy of Pediatrics, the American Thoracic Society, and the American Society for Microbiology.

    • Sarah Ketchikan, AK 11.06.11

      Dr. Hoffman has been a blessing in our lives since the diagnosis of our daughter who has Cysitic Fibrosis. Dr. Hoffman has been our daughter's doctor since 4 months of age. Being from a small isolated community we have traveled countless times to the CF clinic. Dr. Hoffman has been accommodating to us due to difficult travel and has ALWAYS made time to address any questions or concerns big or small. Dr. Hoffman's passion is apparent in the way he interacts with his patients and their families. Dr. Hoffman provides excellent care and considers each step in our daughter's treatment and health maintenance plan carefully. I highly recommend him!

    • Stephanie Lynnwod, WA 03.22.11

      Dr. Hoffman was just a resident when he first cared for our son. Now, as an attending physician, Dr. Hoffman still provides care and consultation for our son, 13 years later. Dr. Hoffman's bedside manner is fantastic. I will always remember him crouching down to speak eye to eye with both patients and parents. His knowledge is extensive and he is always seeking to know more. Finding answers to difficult questions is a strength of Dr. Hoffman's. We highly recommend Dr. Luke Hoffman!

    Recommend Luke Raphael Hoffman, MD, PhD
  • Award Name Award Description Awarded By Award Date
    SEATTLE TOP DOCTOR - 2022 Seattle Magazine 2022
    SEATTLE'S TOP DOCTOR - 2017 Seattle Magazine 2017
    Seattles Top Doctor 2016 Seattle Met Magazine 2016
    Nominee, Seattle Children's Hospita Family Choice Award Seattle Children's Hospital 2014
    Outstanding Teaching Award UW Pediatrics Residency Program 2013
    Research feature http://discover.coverleaf.com/discovermagazine/201009?pg=23#pg23 Discover magazine 2010
    Nominee, Seattle Childrens Hospital Family Choice Award Seattle Childrens Hospital 2009
    Elected Scholar Institute for Translational Health Sciences 2008
    Nominee Seattle Childrens Hospital Family Choice Award 2007
    2006 First author of one of 2005s "Top Articles in Infectious Disease" Pediatric News 2006
    Leroy Matthews Physician Scientist Award 2004 - 2005
    Cystic Fibrosis Foundation Third-year Research Fellowship Training Award Cystic Fibrosis Foundation 2003 - 2004
    Cystic Fibrosis Foundation Clinical Fellowship Second-year Training Award Cystic Fibrosis Foundation 2002 - 2003
    Cystic Fibrosis Foundation Clinical Fellowship First-year Training Award Cystic Fibrosis Foundation 2001 - 2002
    Young Scientist Award Options for the Control of Influenza III, Cairns, Australia 1996
    Richard Fineberg Memorial Student Teaching Award UCSF 1994
    Departmental Citation (valedictorian) College of Chemistry, UC Berkeley 1990
    Invited graduation speaker UC Berkeley 1990
    University Citation, (One of top 10 Univ. grads) UC Berkeley 1990
    Medical Scientist Training Program Award 1990 - 1998
    Thompson Chemistry Scholarship 1988 - 1990
    Regents' Scholarship UC Berkeley 1986 - 1990

  • Other Publications

    • Chang AB, Marsh RL, Smith-Vaughan HC, Hoffman LR
      Emerging drugs for bronchiectasis: an update.
      25736583 Expert opinion on emerging drugs, 2015 Mar 3 : 1-21
    • Chang AB, Marsh RL, Upham JW, Hoffman LR, Smith-Vaughan H, Holt D, Toombs M, Byrnes C, Yerkovich ST, Torzillo PJ, O'Grady KA, Grimwood K
      Toward making inroads in reducing the disparity of lung health in Australian indigenous and new zealand mori children.
      25741502 Frontiers in pediatrics, 2015 : 39 PMCID:PMC4327127
    • Wolter DJ, Hoffman LR
      Strength in diversity.
      25299327 Cell host & microbe, 2014 Oct 8 : 16(4)427-9
    • Hoffman LR, Pope CE, Hayden HS, Heltshe S, Levy R, McNamara S, Jacobs MA, Rohmer L, Radey M, Ramsey BW, Brittnacher MJ, Borenstein E, Miller SI
      Escherichia coli Dysbiosis Correlates With Gastrointestinal Dysfunction in Children With Cystic Fibrosis.
      24178246 Clinical infectious diseases : an official publication of the Infectious Diseases Society of America, 2013 Nov 20
    • McCaughey G, Gilpin DF, Schneiders T, Hoffman LR, McKevitt M, Elborn JS, Tunney MM
      Fosfomycin and tobramycin in combination downregulate nitrate reductase genes narG and narH, resulting in increased activity against Pseudomonas aeruginosa under anaerobic conditions.
      23959314 Antimicrobial agents and chemotherapy, 2013 Nov. : 57(11)5406-14 PMCID:PMC3811241
    • Wolter DJ, Emerson JC, McNamara S, Buccat AM, Qin X, Cochrane E, Houston LS, Rogers GB, Marsh P, Prehar K, Pope CE, Blackledge M, Déziel E, Bruce KD, Ramsey BW, Gibson RL, Burns JL, Hoffman LR
      Staphylococcus aureus small-colony variants are independently associated with worse lung disease in children with cystic fibrosis.
      23625938 Clinical infectious diseases : an official publication of the Infectious Diseases Society of America, 2013 Aug. : 57(3)384-91
    • Hoffman L, Surette M
      What to expect when you're expectorating: cystic fibrosis exacerbations and microbiota.
      23802823 Annals of the American Thoracic Society, 2013 June : 10(3)249-50
    • Rogers GB, Hoffman LR, Carroll MP, Bruce KD
      Interpreting infective microbiota: the importance of an ecological perspective.
      23598051 Trends in microbiology, 2013 June : 21(6)271-6 PMCID:PMC3880558
    • Rogers GB, Cuthbertson L, Hoffman LR, Wing PA, Pope C, Hooftman DA, Lilley AK, Oliver A, Carroll MP, Bruce KD, van der Gast CJ
      Reducing bias in bacterial community analysis of lower respiratory infections.
      23190732 The ISME journal, 2013 April : 7(4)697-706 PMCID:PMC3603400
    • Hoffman LR, Ramsey BW
      Cystic fibrosis therapeutics: the road ahead.
      23276843 Chest, 2013 Jan. : 143(1)207-13 PMCID:PMC3610617
    • Stressmann FA, Rogers GB, van der Gast CJ, Marsh P, Vermeer LS, Carroll MP, Hoffman L, Daniels TW, Patel N, Forbes B, Bruce KD
      Long-term cultivation-independent microbial diversity analysis demonstrates that bacterial communities infecting the adult cystic fibrosis lung show stability and resilience.
      22707521 Thorax, 2012 Oct. : 67(10)867-73
    • Chang AB, Marsh RL, Smith-Vaughan HC, Hoffman LR
      Emerging drugs for bronchiectasis.
      22809423 Expert opinion on emerging drugs, 2012 Sept. : 17(3)361-78
    • Rogers GB, Hoffman LR, Döring G
      Novel concepts in evaluating antimicrobial therapy for bacterial lung infections in patients with cystic fibrosis.
      21775220 Journal of cystic fibrosis : official journal of the European Cystic Fibrosis Society, 2011 Dec. : 10(6)387-400
    • Stressmann FA, Rogers GB, Marsh P, Lilley AK, Daniels TW, Carroll MP, Hoffman LR, Jones G, Allen CE, Patel N, Forbes B, Tuck A, Bruce KD
      Does bacterial density in cystic fibrosis sputum increase prior to pulmonary exacerbation?
      21664196 Journal of cystic fibrosis : official journal of the European Cystic Fibrosis Society, 2011 Sept. : 10(5)357-65
    • Rogers GB, Hoffman LR, Johnson MW, Mayer-Hamblett N, Schwarze J, Carroll MP, Bruce KD
      Using bacterial biomarkers to identify early indicators of cystic fibrosis pulmonary exacerbation onset.
      21405970 Expert review of molecular diagnostics, 2011 March : 11(2)197-206 PMCID:PMC3148893
    • Sanders DB, Bittner RC, Rosenfeld M, Hoffman LR, Redding GJ, Goss CH
      Failure to recover to baseline pulmonary function after cystic fibrosis pulmonary exacerbation.
      20463179 American journal of respiratory and critical care medicine, 2010 Sep 1 : 182(5)627-32
    • Rogers GB, Hoffman LR, Whiteley M, Daniels TW, Carroll MP, Bruce KD
      Revealing the dynamics of polymicrobial infections: implications for antibiotic therapy.
      20554204 Trends in microbiology, 2010 Aug. : 18(8)357-64 PMCID:PMC3034215
    • Elliott D, Burns JL, Hoffman LR
      Exploratory study of the prevalence and clinical significance of tobramycin-mediated biofilm induction in Pseudomonas aeruginosa isolates from cystic fibrosis patients.
      20404125 Antimicrobial agents and chemotherapy, 2010 July : 54(7)3024-6 PMCID:PMC2897298
    • Christen M, Kulasekara HD, Christen B, Kulasekara BR, Hoffman LR, Miller SI
      Asymmetrical distribution of the second messenger c-di-GMP upon bacterial cell division.
      20522779 Science (New York, N.Y.), 2010 Jun 4 : 328(5983)1295-7
    • Carter E, Waldhausen J, Zhang W, Hoffman L, Redding G
      Management of children with empyema: Pleural drainage is not always necessary.
      20425855 Pediatric pulmonology, 2010 May : 45(5)475-80
    • Rogers GB, Carroll MP, Hoffman LR, Walker AW, Fine DA, Bruce KD
      Comparing the microbiota of the cystic fibrosis lung and human gut.
      21326915 Gut microbes, 2010 March : 1(2)85-93 PMCID:PMC3023585
    • Sanders DB, Hoffman LR, Emerson J, Gibson RL, Rosenfeld M, Redding GJ, Goss CH
      Return of FEV1 after pulmonary exacerbation in children with cystic fibrosis.
      20054859 Pediatric pulmonology, 2010 Feb. : 45(2)127-34
    • Hoffman LR, Richardson AR, Houston LS, Kulasekara HD, Martens-Habbena W, Klausen M, Burns JL, Stahl DA, Hassett DJ, Fang FC, Miller SI
      Nutrient availability as a mechanism for selection of antibiotic tolerant Pseudomonas aeruginosa within the CF airway.
      20072604 PLoS pathogens, 2010 Jan 8 : 6(1)e1000712 PMCID:PMC2795201
    • Hoffman LR, Kulasekara HD, Emerson J, Houston LS, Burns JL, Ramsey BW, Miller SI
      Pseudomonas aeruginosa lasR mutants are associated with cystic fibrosis lung disease progression.
      18974024 Journal of cystic fibrosis : official journal of the European Cystic Fibrosis Society, 2009 Jan. : 8(1)66-70 PMCID:PMC2631641
    • White, JM; Hoffman, LR; Arevalo, JH; and Wilson, IA
      Attachment and Entry of Influenza Virus into Host Cells: Pivotal Roles of the Hemagglutinin
      Structural Biology of Viruses, 1997
    • Hoffman, LR; White, JM; and Kuntz, ID
      Fusion Mechanism of the Influenza Hemagglutinin: Inhibitor Design
      Options for the Control of Influenza III: Proceedings, 1996
    • Hoffman, LR
      The Low pH-induced Conformational Change in the Influenza Hemagglutinin: Inhibitor Design
      PhD thesis, UCSF, 1996
    • Hoffman, LR
      How aspirin works
      http://health.howstuffworks.com/aspirin.htm

    Show More Hide

  • Presentations Title Event Location Date
    Omics of airway infection (Symposium chair). 28th Annual North American Cystic Fibrosis Foundation Conference (NACFC) Atlanta, Georgia Oct 11, 2014
    Omics of airway infection (Symposium chair). 28th Annual North American Cystic Fibrosis Foundation Conference (NACFC) Atlanta, Georgia Oct 11, 2014
    Intestinal Dysbiosis in CF 28th Annual North American Cystic Fibrosis Foundation Conference (NACFC) Atlanta, Georgia Oct 9, 2014
    What to expect when youre expectorating: An ecological perspective on chronic infections in the lung and elsewhere Menzies School of Health Research Special Seminar Series, Royal Darwin Hospital Darwin, Australia Jul 29, 2014
    Considerations for sampling in respiratory microbiota studies: Lessons from cystic fibrosis. (presenter and invited session chair) Scientific Workshop for the Centre for Research Excellence in Respiratory Health of Aboriginal and Torres Strait Islander Children, Royal Childrens Hospital Brisbane, Australia Jul 24, 2014
    Potential interaction between inhaled tobramycin and azithromycin. University of Washington Annual Cystic Fibrosis Clinical Conference Seattle, Washington Jul 18, 2014
    Airway microbiome in children: Contribution to health and disease. (Symposium co-chair and panel discussion leader) The 2014 American Thoracic Society Annual Conference San Diego, California May 19, 2014
    Panelist and discussant for "Lung Phenotype of Juvenile and Adult CFTR-Knockout Ferrets" An American Thoracic Society international webinar Jan 10, 2014
    What to expect when youre expectorating: An ecological perspective on chronic respiratory infections University of Minnesota Pediatrics Ground Rounds Minneapolis, Minnesota Dec 11, 2013
    CF lung microbiome: What have we learned? The 27th Annual North American Cystic Fibrosis Foundation Conference (NACFC) Salt Lake City, Utah Oct 24, 2013
    Staphylococcus aureus Small-Colony Variants Are Independently Associated With Worse Lung Disease Children With Cystic Fibrosis The 36th European Cystic Fibrosis Conference Lisbon, Portugal Jun 14, 2013
    Pseudomonas aeruginosa adaptation during early CF airway infection and treatment University of Washington Cystic Fibrosis Research Seminar Series Seattle, WA May 9, 2013
    Bacterial interspecies interactions during chronic infections: From bedside to bench, and back again Montana State University Departmental Seminar for Microbiology, Immunology, and Infectious Disease (chosen by the graduate students Bozeman, Montana Nov 2, 2012
    Microbial Ecology and Emerging Pathogens. (Workshop Chair and speaker) The 26th Annual North American Cystic Fibrosis Foundation Conference (NACFC) Orlando, FL Oct 13, 2012
    Bacterial interspecies interactions during chronic infections: From the bench to bedside, and back again University of Vermont Center of Biomedical Research Excellence in Immunology and Infectious Diseases Seminar Series University of Vermont, Burlington, VT Sep 28, 2012
    Microbial interspecies interactions during chronic polymicrobial infections University of Washington Department of Microbiology Annual Retreat University of Washington, Seattle, WA Sep 21, 2012
    Chronic lung infections in children: Why dont antibiotics work better? University of Washington Department of Pediatrics Principal Investigator Research Seminar Series University of Washington, Seattle, WA Jun 18, 2012
    The prevalence and clinical significance of Staphylococcus aureus small-colony variants in chronic CF lung infections Queens University Belfast School of Pharmacy Seminar Series Queens University Belfast, Northern Ireland Jun 5, 2012
    Describing the CF Gut Microbiome in Infancy and Early Childhood University of Washington Annual CF Retreat, University of Washington Seattle, WA Aug 31, 2011
    Bacterial adaptation during chronic infections: The role of bacterial interspecies interactions Ross University Research Day (Entitled, "Chronic Infections: A Key Frontier in Infectious Diseases", organized by Lucas Hoffman) Ross University, Dominica Jan 21, 2011
    A research approach to chronic, polymicrobial lung infections Kings College London Molecular Microbiology Research Laboratory Research Seminar Series Kings College London, United Kingdom Nov 19, 2010
    Bacterial adaptive changes during chronic, polymicrobial infections: Lessons from cystic fibrosis University of Washington Microbiology Departmental Seminar, University of Washington Seattle, WA Oct 5, 2010
    Cystic fibrosis exacerbations: A deliberately provocative examination of current antibiotic management Seattle CF Center and Affiliate Centers Annual Clinical Conference, University of Washington Seattle, Washington Jul 23, 2010
    Bacterial adaptive changes during chronic, polymicrobial infections: Lessons from cystic fibrosis Stanford University Department of Pediatrics, Center for Excellence in Pulmonary Biology research seminar Palo Alto, CA Feb 9, 2010
    Bacterial Adaptation During Chronic Infections: Lessons from Cystic Fibrosis University of Montana Division of Biological Sciences Departmental Seminar Missoula, MT Dec 7, 2009
    Evolution and Biofilms The 5th International American Society of Microbiology Conference on Biofilms Cancun, Mexico Nov 17, 2009
    Pseudomonas aeruginosa adaptation during early cystic fibrosis infection and treatment: lasR mutation The 23rd Annual North American CF Conference Minneapolis, MN Oct 10, 2009
    Bacterial Adaptation During Chronic Infections: Lessons from Cystic Fibrosis Vanderbilt University Department of Pediatrics Research Conference Nashville, TN Oct 5, 2009
    The Adaptive Significance of Pseudomonas aeruginosa lasR Mutations in CF : Cystic Fibrosis Research Development Program Annual Retreat, Seattle, WA Aug 31, 2009
    Interspecies Microbial Interactions in CF Airways: Lessons from Pseudomonas and Staphylococcus Cystic Fibrosis Research Development Network Seminar Series Seattle, WA 2009

Overview

Board Certification(s)

Pediatric Pulmonology

Medical/Professional School

University of California San Francisco School of Medicine, San Francisco, CA

Residency

University of Washington School of Medicine, Seattle, WA

Fellowship

University of Washington School of Medicine, Seattle, WA

Research Description

We are working to understand why children with chronic lung infections don't improve with antibiotics as predicted based on our knowledge of the microbes involved. As a paradigm for this problem, we focus on the chronic lung infections in people with the genetic disease cystic fibrosis (CF), infections that usually respond incompletely to antibiotics predicted to be effective against the bacteria we know to be present. They exhibit several other characteristics common to many difficult to treat, chronic lung infections, including the following:

1) They frequently include multiple microbial species infecting together, which makes it difficult to know which of these species impact lung disease either by themselves or by interacting with other pathogenic microbes.

2) The chemical and microbial environment in which these infections occur is probably different from that used in laboratory microbial tests, including the availability of nutrients that impact microbial behavior.

Currently, our laboratory studies the behavior of the microbes causing CF and other chronic lung infections in models that attempt to more closely reflect the airway environment, which includes multiple microbial species, antibiotics, and specific nutrients. We hope to identify new and more effective treatments for children with chronic, polymicrobial lung infections, starting with CF.

Research Focus Area

Cystic Fibrosis, Pulmonary